Institution Directory

Clinical trials at Johns Hopkins

Sites in Baltimore, MD

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1430

Shown on this page

Current sort

Live official records

Conditions: Liver Cirrhosis
Interventions: BI 3802876, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Chandler, Arizona • Coronado, California • La Mesa, California + 21 more

Conditions: Idiopathic Inflammatory Myopathies
Interventions: Placebo, Nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 18 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab, Questionnaire Administration, Venetoclax; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 624
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 443 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Pelacarsen (TQJ230); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 83
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 65 more

Conditions: Posterior Fossa Ependymal Tumor
Interventions: Metformin, Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Year to 39 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Systemic Sclerosis
Interventions: Placebo matching nerandomilast formulation 1, Placebo matching nerandomilast formulation 2, Nerandomilast formulation 1, Nerandomilast formulation 2; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more

Conditions: Type B Aortic Dissection
Interventions: TEVAR, Guideline directed medical therapy and surveillance of dissection; Procedure · Other
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more

Conditions: Food Allergy
Interventions: Omalizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple System Atrophy
Interventions: Amlenetug, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Francisco, California + 18 more

Conditions: Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more

Conditions: Endometriosis, Endometrial Diseases
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 135 participants
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Baltimore, Maryland • Nashville, Tennessee

Conditions: Renal Insufficiency, Chronic
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 79 Years
Enrollment: 5,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2028
U.S. locations: 12
States / cities: Oakland, California • San Francisco, California • Chicago, Illinois + 6 more

About this Johns Hopkins institution page

What this page lists: ClinicalTrials.gov records that list Johns Hopkins in Baltimore, MD as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Johns Hopkins

Filter and sort this campus

Live official records

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Pelacarsen Roll-over Extension Program

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food Allergy

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance

SDCC - Prospective Cohort Study of Chronic Renal Insufficiency

About this Johns Hopkins institution page